Most Singaporeans I meet have a retirement number. A CPF LIFE payout, a rental yield, a portfolio drawdown figure. It is usually thoughtful, sometimes spreadsheet-perfect. And almost every one of them has built it on a quiet assumption: that healthcare will cost roughly what it costs today. It is the single most expensive assumption in Singaporean retirement planning, because medical costs in retirement do not behave like anything else in your budget.
That assumption is the probably single largest unfunded liability in Singaporean retirement planning. Here is why — and what to do about it.
Before we go further, one question. When your last Integrated Shield Plan renewal notice arrived, did the number give you a jolt? If it did, you are not imagining it and you are not alone — and the reasons run a great deal deeper than one year’s increase.
Part One: How We Got Here
To understand where your premiums are going, you have to understand how the system was built.
2005 — The “as charged” revolution. Aviva brought the first “as charged” Integrated Shield Plan to Singapore in 2005, removing the inner limits that had previously capped what could be claimed for each procedure. Later, it extended as-charged coverage to outpatient dialysis and cancer treatment.
Competitors matched within months. Inner limits — the old discipline mechanism — largely disappeared for private-hospital plans. It was a genuine breakthrough for policyholders — and it also removed the ceiling on what a hospital bill could be.
Other insurers enhanced their plans with richer benefits, longer pre- and post-hospitalisation coverage and access to private hospitals.
Consumers benefited tremendously.
However, richer benefits also meant that patients became less sensitive to healthcare costs, while hospitals and specialists invested in newer technology and increasingly sophisticated treatments.
2007–2015 — full riders and the buffet problem
Insurers layered on riders covering both deductible and co-insurance, producing near-zero out-of-pocket hospitalisation. Senior Minister of State Chee Hong Tat later described this as a “buffet syndrome,” leading to over-consumption, over-servicing and over-charging. Insurers then layered on riders that absorbed the deductible and co-insurance entirely. Hospitalisation became, almost free.
Medical inflation accelerated.
The data eventually proved him right. Between 2015 and 2020, claims incidence grew at a compound annual rate of about 15% for full riders on private hospital plans. For riders with some co-payment, that figure was close to zero. Average bill sizes on full-rider claims ran at least 20% higher.
2015 — MediShield Life. The national scheme became universal and lifelong, covering all Singaporeans and PRs including those with pre-existing conditions, who pay a 30% additional premium for the first ten years. The catastrophic layer was nationalised. The layers above it stayed private — and stayed exposed.
2016 — Health Insurance Task Force, which recommended fee benchmarks, panel networks, pre-authorisation and co-payment. This set the policy direction for everything after.
2018 — The first correction. MOH mandated a minimum 5% co-payment on all new riders, capped at S$3,000 per policy year. Full riders stopped being sold. Existing ones were grandfathered, creating a closed block of the highest-utilising policyholders that insurers could no longer re-underwrite — only reprice. I wrote about how those earlier rounds of Shield plan changes played out when the Cancer Drug List was first announced.
The data justifying it: between 2015 and 2020, the compound annual growth rate of claims incidence was about 15% for full riders of private hospital IPs and about 9% for restructured hospital IP full riders, versus close to 0% for riders with some co-payment. Average bill size for full-rider claims was at least 20% higher.
2018 onwards — fee benchmarks, panels, claims-based pricing
Insurers rolled out preferred panels, pre-authorisation, and claims-based pricing. Under claims-based pricing, rider premiums at renewal are adjusted based on claims in the previous policy year — with steeper loading for non-panel claims
COVID-19 and the New Reality of Medical Inflation
Between 2020 and 2022, two forces collided to push medical costs sharply higher: global inflation and a backlog of elective surgeries. When restrictions eased, hospitals faced a surge of postponed procedures at the same time supply costs, staffing, and equipment prices were climbing worldwide. The result was a jump in healthcare utilisation and claims that insurers — and ultimately policyholders — are still feeling today.
2021–2023 — The Cancer Drug List.
From September 2022, MediShield Life and MediSave covered only cancer treatments on an approved list. From April 2023, the same applied to Integrated Shield Plans. Previously, most IPs had covered outpatient cancer drugs “as charged” against policy limits that could exceed S$2 million. That is a very large door that has now closed.
Insurers responded in the only way available to them. Cancer treatment and non-CDL drug coverage moved out of the base plan and into the riders — which quietly changed what a rider is for. It had been a convenience, absorbing your deductible and co-insurance. It became the only thing standing between you and the full cost of a treatment your oncologist recommends but the national list does not fund.
That made riders considerably more essential. It also made them considerably more expensive — and it concentrated the cost in the one component that must always be paid in cash. If the co-payment and panel rules still feel opaque, I have a plain-language walkthrough of how IP riders actually work.
April 2025 — MediShield Life enhanced.
Annual claim limit raised from S$150,000 to S$200,000, with higher limits for daily charges, surgery and intensive care. Premiums rise by up to 35%, phased over three years to March 2028, averaging 22% per policyholder. The outpatient deductible arrives 1 June 2026, with the second phase of the inpatient deductible increase on 1 April 2027. The Government is putting S$4.1 billion behind cushioning it.
April 2026 — The second correction.
New IP riders can no longer cover the minimum deductible, which ranges from S$1,500 to S$3,500 depending on ward class. The co-payment cap doubles from S$3,000 to S$6,000. New private hospital riders are roughly 30% cheaper as a result — because they cover roughly 30% less.
Why Premiums Continue to Rise
Several factors now work together.
- Singapore has one of the fastest ageing populations in Asia.
- New medical technology improves outcomes but is more expensive.
- Cancer drugs and biologic therapies can cost tens of thousands of dollars.
- Hospital operating costs continue to increase.
- Doctors and specialists command higher professional fees.
- Medical inflation has consistently exceeded general inflation.
To ensure long-term sustainability, MOH introduced several reforms, including mandatory co-payments for riders, specialist panels, fee benchmarks and tighter reimbursement rules for cancer treatments.
These measures help slow rising claims, but they cannot eliminate medical inflation.
Meanwhile, the insurers have been bleeding
None of these reforms happened in a vacuum. They happened because the business stopped working.
Underwriting results filed with the Monetary Authority of Singapore show almost every Integrated Shield Plan insurer struggling in recent years. Singlife and Income both paid out significantly more than they took in during 2024. Great Eastern reversed its 2023 losses only by raising premiums on its private-grade plans.
Three forces compounded. “As charged” removed the ceiling on what a hospital bill could be. Full riders removed the patient’s reason to care what it was. And medical costs have been rising faster than premiums can be repriced. Layered on top is a grandfathered block of pre-2019 full riders that cannot be re-underwritten and attracts the heaviest claimants. MOH’s own figures show private-hospital policyholders with riders are 1.4 times as likely to claim, with average claim sizes 1.4 times higher.
Here is why that matters to you rather than to shareholders. An insurer losing money on a book of business has exactly one lever, and it is your premium. Every rate card is non-guaranteed. When you open that renewal notice and the number has jumped, you are not being singled out — you are seeing an industry repricing a product that was mispriced for fifteen years.
Part Two: The Escalation, In Numbers
Two different numbers get quoted in this conversation, and confusing them is where most planning goes wrong.
The consumer number. Singapore’s CPI-Healthcare rose 59.1% between 2005 and 2025 — a compound rate of about 2.35% a year, modestly ahead of headline inflation at 2.14%. That sounds manageable. It is also the number that lulls people into complacency.
The insurance number. Medical trend rates — what it actually costs to insure a population, factoring in utilisation, treatment intensity and new therapies — tell a different story. Aon forecast an 11.1% rise across Asia-Pacific for 2025. Mercer Marsh Benefits forecast 12.5% for Asia in 2026, the sixth consecutive year of double-digit trends. The Life Insurance Association Singapore has pointed to Singapore medical costs rising 16.9% in 2026.
The gap between 2.35% and 12% is not a rounding error. It is the difference between a retirement plan that holds and one that doesn’t.
Why the divergence? CPI measures the price of a consultation. Medical trend measures the cost of treating a person — and we are consuming more scans, more procedures, more biologics, and living longer with more chronic conditions while doing it. Your premium is priced off the second number, not the first.
There is a second escalator working alongside it: you also get older. Integrated Shield premiums step up sharply by age band, independently of inflation. A 45-year-old is not simply paying today’s premium plus inflation at 65 — they are paying the 65-year-old premium, inflated for twenty years of medical trend. Two multipliers, stacked.
What that looks like on a real rate card
Let me put actual numbers to it, because the abstraction does not land the way the arithmetic does.
Take a 35-year-old on a private-hospital Integrated Shield Plan with a rider — the standard arrangement for a working professional in Singapore. The figures below are the cash portion of the annual premium, taken from a major insurer’s published 2026 rate card. Not projections. Not estimates. What the table says today.
That is a 22.6-fold increase — and not a single dollar of medical inflation has been applied to it.
This is the number that breaks retirement plans. Nobody budgets a line item that grows twenty-two-fold. People anchor on what they pay today, quietly assume it drifts up with general inflation, and build a retirement number on that assumption.
Two features of this table deserve attention.
First, the shape. The cost does not rise smoothly. It is flat-ish through your thirties and forties, steepens through your fifties and sixties, and accelerates hardest after seventy. Across the full span from 35 to 85, 64% of the total cash cost falls after age 71 — in the fifteen years when employment income has ended and MediSave contributions have stopped.
Second, the cash. MediSave carries the MediShield Life portion and part of the plan premium, but rider premiums must be paid in cash, always. On a private-hospital arrangement, MediSave covers only about a fifth of the lifetime bill. The remainder comes from your pocket, every year, for as long as you live.
Add the two escalators together and the totals are sobering. Summed across ages 35 to 85 at today’s rates, that private-hospital arrangement costs roughly S$331,000 in cash. Apply even a modest 4% annual repricing — well below the medical trend rates cited above, and insurers do reprice — and the lifetime cash figure approaches S$1.5 million.
Figures derived from a major Singapore insurer’s published premium rates effective 1 April 2026, for a standard life on a private-hospital plan with rider, excluding any no-claims discount. Premium rates are not guaranteed and may be revised by the insurer. Your own figures will differ by insurer, plan, ward class, health status and claims history.
Part Three: What Medical Costs in Retirement Do to Your Plan
Here is the uncomfortable arithmetic.
1. Your medical premium is a lifetime liability, not an annual expense.
Most people budget for their Shield plan the way they budget for a mobile plan — a monthly line item. But you will pay this premium every year for the rest of your life, and it will grow faster than your CPF LIFE payout, faster than your bond coupons, and faster than most people’s dividend income.
The table above makes the scale of it concrete. The S$12,178 a year at 75 is the figure worth sitting with — not because it is unaffordable, but because it has to come from somewhere, and in most plans I review, nothing has been set aside for it.
MediSave helps, but MediSave withdrawal limits are fixed dollar amounts that do not index — S$300, S$600 and S$900 a year depending on age — while the premium climbs. And MediSave contributions stop when you stop working. Rider premiums must be paid in cash, always. That is a cash obligation running into your eighties and nineties, at a growth rate you do not control.
2. Your out-of-pocket exposure has been deliberately increased.
From April 2026, a private-hospital policyholder on a new rider faces up to S$3,500 in deductible plus up to S$6,000 in co-payment. Around S$9,500 a year of exposure that no rider is legally permitted to absorb. This is by design — MOH is restoring the price signal.
That is manageable at 45 with an income. At 72, on a fixed drawdown, in a year with two admissions, it is a different conversation entirely.
3. The catastrophic layer is covered. The chronic decades are not.
MediShield Life protects you against the S$200,000 event. Retirement healthcare is rarely one large event. It is fifteen years of specialist reviews, medications, scans, day surgeries, physiotherapy, and eventually help with daily living — the accumulation, not the catastrophe. Almost none of that is what a hospital plan was designed for.
4. Non-CDL cancer treatment is now a cash problem.
The Cancer Drug List has done its job in controlling costs. But if the treatment your oncologist recommends sits outside the list, the funding gap falls to your rider, a critical illness policy, or your savings. For a retiree, “your savings” means selling assets at whatever price the market offers that quarter.
Part Four: What a Sound Plan Actually Looks Like
I do not think the answer is to buy more insurance. I think the answer is to plan for medical costs the way we plan for any other long-duration, inflating liability — deliberately, with the right instrument for each layer.
Layer 1 — Keep the base intact. Never let a Shield plan lapse to save premium. Underwriting is a one-way door; you can always downgrade the ward class or drop to a public-hospital plan, but you cannot buy back health you have since lost. More on this on my health insurance planning page.
Layer 2 — Fund the deductible and co-payment deliberately. Ring-fence a dedicated medical reserve, sized to cover several years of the S$9,500 maximum exposure, held in cash or near-cash. Not “I’ll take it from the portfolio.” Take it from a bucket that exists for exactly this.
Layer 3 — Build a retirement medical premium fund. This is the piece almost nobody does. If your Shield and rider premiums at 70 will be several times today’s figure, that liability deserves its own asset, accumulated during your earning years. An endowment, an annuity stream, or a dedicated portfolio sleeve — the vehicle matters less than the earmarking. This sits inside the wider question of retirement planning, and the earlier you start, the less it costs — as I set out in the cost of waiting.
Layer 4 — Cover what hospital plans structurally cannot. Critical illness for income replacement and non-CDL treatment. Hospital cash for the days themselves. Long-term care — CareShield Life plus supplements — for the years when the problem is not a hospital at all. I have covered CareShield Life and supplements separately.
Layer 5 — Review the grandfathered full riders. If you have held a pre-2019 full rider, you are in the block insurers most want to reprice. Whether to stay or switch depends on your age, your health, and whether you would survive fresh underwriting. That is not a decision to make from a marketing email. It is a decision to make with your numbers in front of you.
The Point
Singapore’s healthcare financing system is one of the best-designed in the world. Every reform since 2018 has moved in one consistent direction: the state guarantees you against catastrophe, and asks you to own the first dollars of your care.
That is sound policy. It is also a transfer of risk — to you, over a retirement that may run thirty years, against a cost curve compounding at double digits.
The plan you built five years ago probably did not price that in. Most didn’t.
Gilbert Koh is an Independent Financial Adviser and MDRT Life Member based in Singapore, representing Avallis Financial. He holds a BBA (Finance) from the National University of Singapore and specialises in protection, wealth accumulation, education and retirement planning for career-progressive Singaporeans and PRs.
Reach him at gilbert@avallis.com
Sources: Ministry of Health Singapore; CPF Board; Singapore Department of Statistics; Aon 2025 Global Medical Trend Rates Report; Mercer Marsh Benefits 2026 Health Trends; Life Insurance Association Singapore. Figures accurate as at July 2026. This article is for general information and does not constitute financial advice. Please seek advice tailored to your circumstances before making any decision.
